Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1—infected subjects with genotypic evidence of RAL re...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2013-03, Vol.207 (5), p.740-748 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 748 |
|---|---|
| container_issue | 5 |
| container_start_page | 740 |
| container_title | The Journal of infectious diseases |
| container_volume | 207 |
| creator | Eron, Joseph J. Clotet, Bonaventura Durant, Jacques Katlama, Christine Kumar, Princy Lazzarin, Adriano Poizot-Martin, Isabelle Richmond, Gary Soriano, Vincent Ait-Khaled, Mounir Fujiwara, Tamio Huang, Jenny Min, Sherene Vavro, Cindy Yeo, Jane |
| description | Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1—infected subjects with genotypic evidence of RAL resistance. Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was |
| doi_str_mv | 10.1093/infdis/jis750 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3563307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23354743</jstor_id><sourcerecordid>23354743</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-45893a04739a9a05ffc0e14770b7c5b5b261f707ccc4504ecbeac3e8d1d52cc43</originalsourceid><addsrcrecordid>eNpV0UFv0zAYBmALgVg3OHIE-YLEJcyO7bjhgIRG2SImkNayHSPH-by6pE6xnWn5K_xaDOmqcbJkP99rWy9Cryh5T0nJTq0zrQ2nGxukIE_QjAoms6Kg7CmaEZLnGZ2X5RE6DmFDCOGskM_RUc7yXJSEztDvpTIQR6xcixfGWK30iHuDP_fdEOHWqzvrsXV45UHFLbiYLe534C04DS1eDs0GdAz4xsY1vlLdw0h2BcGGqFzEF9U1Xo07wBRXziRte_cB5zy7AfiJkxu6FJCujGvA19XX6ts5XsahHV-gZ0Z1AV7u1xP048tidXaRXX4_r84-XWaayzxmXMxLpgiXrFSlIsIYTYByKUkjtWhEkxfUSCK11lwQDroBpRnMW9qKPO2xE_Rxyt0NzRZanT7pVVfvvN0qP9a9svX_J86u69v-rmaiYIzIFPBuH-D7XwOEWG9t0NB1ykE_hJoWgheSzHORaDZR7fsQPJjDNZTUf_uspz7rqc_k3zx-20E_FJjA2z1QQavOeOV0Gj84SSnh_9zryW1C7P2jHCa45Iz9AdPStrc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1654670825</pqid></control><display><type>article</type><title>Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Eron, Joseph J. ; Clotet, Bonaventura ; Durant, Jacques ; Katlama, Christine ; Kumar, Princy ; Lazzarin, Adriano ; Poizot-Martin, Isabelle ; Richmond, Gary ; Soriano, Vincent ; Ait-Khaled, Mounir ; Fujiwara, Tamio ; Huang, Jenny ; Min, Sherene ; Vavro, Cindy ; Yeo, Jane</creator><creatorcontrib>Eron, Joseph J. ; Clotet, Bonaventura ; Durant, Jacques ; Katlama, Christine ; Kumar, Princy ; Lazzarin, Adriano ; Poizot-Martin, Isabelle ; Richmond, Gary ; Soriano, Vincent ; Ait-Khaled, Mounir ; Fujiwara, Tamio ; Huang, Jenny ; Min, Sherene ; Vavro, Cindy ; Yeo, Jane ; VIKING Study Group ; for the VIKING Study Group</creatorcontrib><description>Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1—infected subjects with genotypic evidence of RAL resistance. Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was <400 copies/mL. Results. A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen. Conclusion. Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jis750</identifier><identifier>PMID: 23225901</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - adverse effects ; Anti-HIV Agents - pharmacology ; Antiretroviral Therapy, Highly Active - methods ; Biological and medical sciences ; Drug Resistance, Viral ; Female ; Fundamental and applied biological sciences. Psychology ; Heterocyclic Compounds, 3-Ring - administration & dosage ; Heterocyclic Compounds, 3-Ring - adverse effects ; Heterocyclic Compounds, 3-Ring - pharmacology ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-1 - drug effects ; HIV-1 - isolation & purification ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Infectious diseases ; Major and Brief Reports ; MAJOR ARTICLES AND BRIEF REPORTS ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; Pilot Projects ; Plasma - virology ; Pyrrolidinones - pharmacology ; Raltegravir Potassium ; RNA, Viral - blood ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load ; Virology ; Young Adult</subject><ispartof>The Journal of infectious diseases, 2013-03, Vol.207 (5), p.740-748</ispartof><rights>Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>2014 INIST-CNRS</rights><rights>The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-45893a04739a9a05ffc0e14770b7c5b5b261f707ccc4504ecbeac3e8d1d52cc43</citedby><cites>FETCH-LOGICAL-c472t-45893a04739a9a05ffc0e14770b7c5b5b261f707ccc4504ecbeac3e8d1d52cc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23354743$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23354743$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27110401$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23225901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eron, Joseph J.</creatorcontrib><creatorcontrib>Clotet, Bonaventura</creatorcontrib><creatorcontrib>Durant, Jacques</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>Kumar, Princy</creatorcontrib><creatorcontrib>Lazzarin, Adriano</creatorcontrib><creatorcontrib>Poizot-Martin, Isabelle</creatorcontrib><creatorcontrib>Richmond, Gary</creatorcontrib><creatorcontrib>Soriano, Vincent</creatorcontrib><creatorcontrib>Ait-Khaled, Mounir</creatorcontrib><creatorcontrib>Fujiwara, Tamio</creatorcontrib><creatorcontrib>Huang, Jenny</creatorcontrib><creatorcontrib>Min, Sherene</creatorcontrib><creatorcontrib>Vavro, Cindy</creatorcontrib><creatorcontrib>Yeo, Jane</creatorcontrib><creatorcontrib>VIKING Study Group</creatorcontrib><creatorcontrib>for the VIKING Study Group</creatorcontrib><title>Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1—infected subjects with genotypic evidence of RAL resistance. Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was <400 copies/mL. Results. A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen. Conclusion. Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Biological and medical sciences</subject><subject>Drug Resistance, Viral</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heterocyclic Compounds, 3-Ring - administration & dosage</subject><subject>Heterocyclic Compounds, 3-Ring - adverse effects</subject><subject>Heterocyclic Compounds, 3-Ring - pharmacology</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - isolation & purification</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Major and Brief Reports</subject><subject>MAJOR ARTICLES AND BRIEF REPORTS</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Pilot Projects</subject><subject>Plasma - virology</subject><subject>Pyrrolidinones - pharmacology</subject><subject>Raltegravir Potassium</subject><subject>RNA, Viral - blood</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><subject>Virology</subject><subject>Young Adult</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpV0UFv0zAYBmALgVg3OHIE-YLEJcyO7bjhgIRG2SImkNayHSPH-by6pE6xnWn5K_xaDOmqcbJkP99rWy9Cryh5T0nJTq0zrQ2nGxukIE_QjAoms6Kg7CmaEZLnGZ2X5RE6DmFDCOGskM_RUc7yXJSEztDvpTIQR6xcixfGWK30iHuDP_fdEOHWqzvrsXV45UHFLbiYLe534C04DS1eDs0GdAz4xsY1vlLdw0h2BcGGqFzEF9U1Xo07wBRXziRte_cB5zy7AfiJkxu6FJCujGvA19XX6ts5XsahHV-gZ0Z1AV7u1xP048tidXaRXX4_r84-XWaayzxmXMxLpgiXrFSlIsIYTYByKUkjtWhEkxfUSCK11lwQDroBpRnMW9qKPO2xE_Rxyt0NzRZanT7pVVfvvN0qP9a9svX_J86u69v-rmaiYIzIFPBuH-D7XwOEWG9t0NB1ykE_hJoWgheSzHORaDZR7fsQPJjDNZTUf_uspz7rqc_k3zx-20E_FJjA2z1QQavOeOV0Gj84SSnh_9zryW1C7P2jHCa45Iz9AdPStrc</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Eron, Joseph J.</creator><creator>Clotet, Bonaventura</creator><creator>Durant, Jacques</creator><creator>Katlama, Christine</creator><creator>Kumar, Princy</creator><creator>Lazzarin, Adriano</creator><creator>Poizot-Martin, Isabelle</creator><creator>Richmond, Gary</creator><creator>Soriano, Vincent</creator><creator>Ait-Khaled, Mounir</creator><creator>Fujiwara, Tamio</creator><creator>Huang, Jenny</creator><creator>Min, Sherene</creator><creator>Vavro, Cindy</creator><creator>Yeo, Jane</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20130301</creationdate><title>Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study</title><author>Eron, Joseph J. ; Clotet, Bonaventura ; Durant, Jacques ; Katlama, Christine ; Kumar, Princy ; Lazzarin, Adriano ; Poizot-Martin, Isabelle ; Richmond, Gary ; Soriano, Vincent ; Ait-Khaled, Mounir ; Fujiwara, Tamio ; Huang, Jenny ; Min, Sherene ; Vavro, Cindy ; Yeo, Jane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-45893a04739a9a05ffc0e14770b7c5b5b261f707ccc4504ecbeac3e8d1d52cc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Biological and medical sciences</topic><topic>Drug Resistance, Viral</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heterocyclic Compounds, 3-Ring - administration & dosage</topic><topic>Heterocyclic Compounds, 3-Ring - adverse effects</topic><topic>Heterocyclic Compounds, 3-Ring - pharmacology</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - isolation & purification</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Major and Brief Reports</topic><topic>MAJOR ARTICLES AND BRIEF REPORTS</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Pilot Projects</topic><topic>Plasma - virology</topic><topic>Pyrrolidinones - pharmacology</topic><topic>Raltegravir Potassium</topic><topic>RNA, Viral - blood</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><topic>Virology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eron, Joseph J.</creatorcontrib><creatorcontrib>Clotet, Bonaventura</creatorcontrib><creatorcontrib>Durant, Jacques</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>Kumar, Princy</creatorcontrib><creatorcontrib>Lazzarin, Adriano</creatorcontrib><creatorcontrib>Poizot-Martin, Isabelle</creatorcontrib><creatorcontrib>Richmond, Gary</creatorcontrib><creatorcontrib>Soriano, Vincent</creatorcontrib><creatorcontrib>Ait-Khaled, Mounir</creatorcontrib><creatorcontrib>Fujiwara, Tamio</creatorcontrib><creatorcontrib>Huang, Jenny</creatorcontrib><creatorcontrib>Min, Sherene</creatorcontrib><creatorcontrib>Vavro, Cindy</creatorcontrib><creatorcontrib>Yeo, Jane</creatorcontrib><creatorcontrib>VIKING Study Group</creatorcontrib><creatorcontrib>for the VIKING Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eron, Joseph J.</au><au>Clotet, Bonaventura</au><au>Durant, Jacques</au><au>Katlama, Christine</au><au>Kumar, Princy</au><au>Lazzarin, Adriano</au><au>Poizot-Martin, Isabelle</au><au>Richmond, Gary</au><au>Soriano, Vincent</au><au>Ait-Khaled, Mounir</au><au>Fujiwara, Tamio</au><au>Huang, Jenny</au><au>Min, Sherene</au><au>Vavro, Cindy</au><au>Yeo, Jane</au><aucorp>VIKING Study Group</aucorp><aucorp>for the VIKING Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>207</volume><issue>5</issue><spage>740</spage><epage>748</epage><pages>740-748</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1—infected subjects with genotypic evidence of RAL resistance. Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log10 copies/mL from baseline or was <400 copies/mL. Results. A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen. Conclusion. Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>23225901</pmid><doi>10.1093/infdis/jis750</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2013-03, Vol.207 (5), p.740-748 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3563307 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Anti-HIV Agents - pharmacology Antiretroviral Therapy, Highly Active - methods Biological and medical sciences Drug Resistance, Viral Female Fundamental and applied biological sciences. Psychology Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - pharmacology HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects HIV-1 - isolation & purification Human immunodeficiency virus 1 Human viral diseases Humans Infectious diseases Major and Brief Reports MAJOR ARTICLES AND BRIEF REPORTS Male Medical sciences Microbiology Middle Aged Miscellaneous Pilot Projects Plasma - virology Pyrrolidinones - pharmacology Raltegravir Potassium RNA, Viral - blood Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Virology Young Adult |
| title | Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A04%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Dolutegravir%20in%20Treatment-Experienced%20Subjects%20With%20Raltegravir-Resistant%20HIV%20Type%201%20Infection:%2024-Week%20Results%20of%20the%20VIKING%20Study&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Eron,%20Joseph%20J.&rft.aucorp=VIKING%20Study%20Group&rft.date=2013-03-01&rft.volume=207&rft.issue=5&rft.spage=740&rft.epage=748&rft.pages=740-748&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/jis750&rft_dat=%3Cjstor_pubme%3E23354743%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1654670825&rft_id=info:pmid/23225901&rft_jstor_id=23354743&rfr_iscdi=true |